Strategies to overcome host immunity to adenovirus vectors in vaccine development

Expert Review of Vaccines

Volumn 8, Issue 6, 2009, Pages 761-777

  Thacker, Erin E ^b   Timares, Laura ^a   Matthews, Qiana L ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Adenovirus vector; Gene therapy; Pre existing immunity; Toxicity; Vaccine

Indexed keywords

ADENOVIRUS 5 VECTOR; ADENOVIRUS VECTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG; VACCINE;

ACUTE TOXICITY; ANTIGEN RECOGNITION; ANTIGENICITY; CELLULAR IMMUNITY; GENE THERAPY; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ADENOVIRIDAE; ANIMALS; GENETIC VECTORS; HUMANS; MICE; PRIMATES; VACCINES;

EID: 67049160649     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.29     Document Type: Review

References (211)

1. Shirakawa T. The current status of adenovirus-based cancer gene therapy. Mol. Cell. 25(4), 462-466 (2008).
2. Douglas JT. Adenoviral vectors for gene therapy. Mol. Biotechnol. 36(1), 71-80 (2007). (Pubitemid 350133603)
3. Campos SK, Barry MA. Current advances and future challenges in adenoviral vector biology and targeting. Curr. Gene Ther. 7(3), 189-204 (2007). (Pubitemid 46902201)
4. Goncalves MA, de Vries AA. Adenovirus: from foe to friend. Rev. Med. Virol. 16(3), 167-186 (2006).
5. Hartman ZC, Black EP, Amalfitano A. Adenoviral infection induces a multi-faceted innate cellular immune response that is mediated by the Toll-like receptor pathway in A549 cells. Virology 358(2), 357-372 (2007). (Pubitemid 46136424)
6. Bai M, Harfe B, Freimuth P. Mutations that alter an Arg-Gly-Asp (RGD) sequence in the adenovirus type 2 penton base protein abolish its cell-rounding activity and delay virus reproduction in flat cells. J. Virol. 67(9), 5198-5205 (1993). (Pubitemid 23241350)
7. Bergelson JM, Cunningham JA, Droguett G et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275(5304), 1320-1323 (1997). (Pubitemid 27114163)
8. Xia D, Henry LJ, Gerard RD, Deisenhofer J. Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7 Å resolution. Structure 2(12), 1259-1270 (1994). (Pubitemid 124001323)
9. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins α v β 3 and α v β 5 promote adenovirus internalization but not virus attachment. Cell 73(2), 309-319 (1993). (Pubitemid 23123309)
10. Wiethoff CM, Wodrich H, Gerace L, Nemerow GR. Adenovirus protein VI mediates membrane disruption following capsid disassembly. J. Virol. 79(4), 1992-2000 (2005). (Pubitemid 40204556)
11. Greber UF, Willetts M, Webster P, Helenius A. Stepwise dismantling of adenovirus 2 during entry into cells. Cell 75(3), 477-486 (1993). (Pubitemid 23335073)
12. Saphire AC, Guan T, Schirmer EC, Nemerow GR, Gerace L. Nuclear import of adenovirus DNA in vitro involves the nuclear protein import pathway and hsc70. J. Biol. Chem. 275(6), 4298-4304 (2000). (Pubitemid 30094670)
13. Trotman LC, Mosberger N, Fornerod M, Stidwill RP, Greber UF. Import of adenovirus DNA involves the nuclear pore complex receptor CAN/Nup214 and histone H1. Nat. Cell Biol. 3(12), 1092-1100 (2001). (Pubitemid 33130460)
14. Greber UF, Suomalainen M, Stidwill RP et al. The role of the nuclear pore complex in adenovirus DNA entry. EMBO J. 16(19), 5998-6007 (1997). (Pubitemid 27427295)
15. Schnell MA, Zhang Y, Tazelaar J et al. Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors. Mol. Ther. 3(5 Pt 1), 708-722 (2001). (Pubitemid 32509868)
16. Raper SE, Chirmule N, Lee FS et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 80(1-2), 148-158 (2003). (Pubitemid 37272241)
17. Muruve DA, Barnes MJ, Stillman IE, Libermann TA. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum. Gene Ther. 10(6), 965-976 (1999). (Pubitemid 29195426)
18. Lieber A, He CY, Meuse L et al. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J. Virol. 71(11), 8798-8807 (1997). (Pubitemid 27446464)
19. Zhang Y, Chirmule N, Gao GP et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol. Ther. 3(5 Pt 1), 697-707 (2001). (Pubitemid 32509867)
20. Cichon G, Boeckh-Herwig S, Schmidt HH et al. Complement activation by recombinant adenoviruses. Gene Ther. 8(23), 1794- (2001). (Pubitemid 34100580)
21. Jiang H, Wang Z, Serra D, Frank MM, Amalfitano A. Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies. Mol. Ther. 10(6), 1140-1142 (2004). (Pubitemid 39625257)
22. Kiang A, Hartman ZC, Everett RS et al. Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system. Mol. Ther. 14(4), 588-598 (2006). (Pubitemid 44296088)
23. Mistchenko AS, Lenzi HL, Thompson FM et al. Participation of immune complexes in adenovirus infection. Acta Paediatr. 81(12), 983-988 (1992). (Pubitemid 23044772)
24. Machemer T, Engler H, Tsai V et al. Characterization of hemodynamic events following intravascular infusion of recombinant adenovirus reveals possible solutions for mitigating cardiovascular responses. Mol. Ther. 12(2), 254-263 (2005). (Pubitemid 41025095)
25. Tao N, Gao GP, Parr M et al. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol. Ther. 3(1), 28-35 (2001). (Pubitemid 32509802)
26. Schiedner G, Bloch W, Hertel S et al. A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. Hum. Gene Ther. 14(17), 1631-1641 (2003). (Pubitemid 37452873)
27. Bruder JT, Kovesdi I. Adenovirus infection stimulates the Raf/MAPK signaling pathway and induces interleukin-8 expression. J. Virol. 71(1), 398-404 (1997). (Pubitemid 26412305)
28. Suomalainen M, Nakano MY, Boucke K, Keller S, Greber UF. Adenovirus-activated PKA and p38/MAPK pathways boost microtubule-mediated nuclear targeting of virus. EMBO J. 20(6), 1310-1319 (2001).
29. Tibbles LA, Spurrell JC, Bowen GP et al. Activation of p38 and ERK signaling during adenovirus vector cell entry lead to expression of the C-X-C chemokine IP-10. J. Virol. 76(4), 1559-1568 (2002). (Pubitemid 34094602)
30. Liu Q, White LR, Clark SA et al. Akt/protein kinase B activation by adenovirus vectors contributes to NFkB-dependent CXCL10 expression. J. Virol. 79(23), 14507-14515 (2005). (Pubitemid 41636249)
31. Parker AL, Nicklin SA, Baker AH. Interactions of adenovirus vectors with blood: implications for intravascular gene therapy applications. Curr. Opin. Mol. Ther. 10(5), 439-448 (2008).
32. Sakurai H, Kawabata K, Sakurai F, Nakagawa S, Mizuguchi H. Innate immune response induced by gene delivery vectors. Int. J. Pharm. 354(1-2), 9-15 (2008).
33. Hartman ZC, Appledorn DM, Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res. 132(1-2), 1-14 (2008).
34. Wu TL, Ertl HC. Immune barriers to successful gene therapy. Trends Mol. Med. 15(1), 32-39 (2009).
35. Zinn KR, Szalai AJ, Stargel A, Krasnykh V, Chaudhuri TR. Bioluminescence imaging reveals a significant role for complement in liver transduction following intravenous delivery of adenovirus. Gene Ther. 11(19), 1482-1486 (2004). (Pubitemid 39359439)
36. Appledorn DM, McBride A, Seregin S et al. Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors. Gene Ther. 15(24), 1606-1617 (2008).
37. Xu Z, Tian J, Smith JS, Byrnes AP. Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J. Virol. 82(23), 11705-11713 (2008).
38. Cichon G, Schmidt HH, Benhidjeb T et al. Intravenous administration of recombinant adenoviruses causes thrombocytopenia, anemia and erythroblastosis in rabbits. J. Gene Med. 1(5), 360-371 (1999). (Pubitemid 129631136)
39. Stone D, Liu Y, Shayakhmetov D et al. Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver. J. Virol. 81(9), 4866-4871 (2007). (Pubitemid 46668683)
40. Othman M, Labelle A, Mazzetti I, Elbatarny HS, Lillicrap D. Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. Blood 109(7), 2832-2839 (2007). (Pubitemid 46482078)
41. Cotter MJ, Zaiss AK, Muruve DA. Neutrophils interact with adenovirus vectors via Fc receptors and complement receptor 1. J. Virol. 79(23), 14622-14631 (2005). (Pubitemid 41636261)
42. Shayakhmetov DM, Gaggar A, Ni S, Li ZY, Lieber A. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J. Virol. 79(12), 7478-7491 (2005). (Pubitemid 40756784)
43. Parker AL, Waddington SN, Nicol CG et al. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 108(8), 2554-2561 (2006). (Pubitemid 44776988)
44. Smith JG, Cassany A, Gerace L, Ralston R, Nemerow GR. Neutralizing antibody blocks adenovirus infection by arresting microtubule-dependent cytoplasmic transport. J. Virol. 82(13), 6492-6500 (2008).
45. Haisma HJ, Kamps JA, Kamps GK et al. Polyinosinic acid enhances delivery of adenovirus vectors in vivo by preventing sequestration in liver macrophages. J. Gen. Virol. 89(Pt 5), 1097-1105 (2008).
46. Smith JG, Nemerow GR. Mechanism of adenovirus neutralization by human α-defensins. Cell Host Microbe 3(1), 11-19 (2008).
47. Ginsberg HS. The ups and downs of adenovirus vectors. Bull. NY Acad. Med. 73(1), 53-58 (1996). (Pubitemid 126815160)
48. Chirmule N, Propert K, Magosin S et al. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 6(9), 1574-1583 (1999). (Pubitemid 29465516)
49. Kass-Eisler A, Falck-Pedersen E, Elfenbein DH et al. The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer. Gene Ther. 1(6), 395-402 (1994). (Pubitemid 2165270)
50. Kass-Eisler A, Leinwand L, Gall J, Bloom B, Falck-Pedersen E. Circumventing the immune response to adenovirus-mediated gene therapy. Gene Ther. 3(2), 154-162 (1996). (Pubitemid 26117425)
51. Wohlfart C. Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms. J. Virol. 62(7), 2321-2328 (1988). (Pubitemid 18156580)
52. + T-cell responses from healthy adults. Viral Immunol. 14(4), 403-413 (2001).
53. Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. Science 270(5235), 404-410 (1995).
54. + CTLs in vivo. J. Immunol. 155(5), 2564-2570 (1995).
55. + T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J. Virol. 78(6), 2666-2673 (2004).
56. McKelvey T, Tang A, Bett AJ, Casimiro DR, Chastain M. T-cell response to adenovirus hexon and DNA-binding protein in mice. Gene Ther. 11(9), 791-796 (2004). (Pubitemid 38659758)
57. Molinier-Frenkel V, Gahery-Segard H, Mehtali M et al. Immune response to recombinant adenovirus in humans: capsid components from viral input are targets for vector-specific cytotoxic T lymphocytes. J. Virol. 74(16), 7678-7682 (2000). (Pubitemid 30613117)
58. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392(6671), 86-89 (1998). (Pubitemid 28150594)
59. Muruve DA, Petrilli V, Zaiss AK et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 452(7183), 103-107 (2008).
60. Cerullo V, Seiler MP, Mane V et al. Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Mol. Ther. 15(2), 378-385 (2007). (Pubitemid 46111889)
61. Iacobelli-Martinez M, Nemerow GR. Preferential activation of Toll-like receptor nine by CD46-utilizing adenoviruses. J. Virol. 81(3), 1305-1312 (2007). (Pubitemid 46167851)
62. Basner-Tschakarjan E, Gaffal E, O'Keeffe M et al. Adenovirus efficiently transduces plasmacytoid dendritic cells resulting in TLR9-dependent maturation and IFN-α production. J. Gene Med. 8(11), 1300-1306 (2006). (Pubitemid 44782509)
63. Zhu J, Huang X, Yang Y. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J. Virol. 81(7), 3170-3180 (2007). (Pubitemid 46456626)
64. Appledorn DM, Patial S, McBride A et al. Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. J. Immunol. 181(3), 2134-2144 (2008).
65. Jankovic D, Liu Z, Gause WC. Th1- and Th2-cell commitment during infectious disease: asymmetry in divergent pathways. Trends Immunol. 22(8), 450-457 (2001). (Pubitemid 32709980)
66. Vujanovic L, Whiteside TL, Potter DM et al. Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus. Cancer Immunol. Immunother. 58(1), 121-133 (2009).
67. + helper T-cell responses in healthy donors and HCC patients. J. Immunother. 30(4), 425-437 (2007).
68. Schumacher L, Ribas A, Dissette VB et al. Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses. J. Immunother. 27(3), 191-200 (2004). (Pubitemid 39118083)
69. Lundqvist A, Choudhury A, Nagata T et al. Recombinant adenovirus vector activates and protects human monocyte-derived dendritic cells from apoptosis. Hum. Gene Ther. 13(13), 1541-1549 (2002). (Pubitemid 35034674)
70. Varnavski AN, Schlienger K, Bergelson JM, Gao GP, Wilson JM. Efficient transduction of human monocyte-derived dendritic cells by chimpanzee-derived adenoviral vector. Hum. Gene Ther. 14(6), 533-544 (2003). (Pubitemid 36438938)
71. Korst RJ, Mahtabifard A, Yamada R, Crystal RG. Effect of adenovirus gene transfer vectors on the immunologic functions of mouse dendritic cells. Mol. Ther. 5(3), 307-315 (2002). (Pubitemid 34211226)
72. Dietz AB, Vuk-Pavlovic S. High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood 91(2), 392-398 (1998). (Pubitemid 28053360)
73. Hirschowitz EA, Weaver JD, Hidalgo GE, Doherty DE. Murine dendritic cells infected with adenovirus vectors show signs of activation. Gene Ther. 7(13), 1112-1120 (2000). (Pubitemid 30458802)
74. Calcedo R, Vandenberghe LH, Roy S et al. Host immune responses to chronic adenovirus infections in human and nonhuman primates. J. Virol. 83(6), 2623-2631 (2009). •• Reveals profound differences in adenovirus (Ad) pathogenesis and immune response mechanisms that are elaborated in nonhuman primates, as compared with humans. Differences in nonhuman primate-specific Ad subgroups are also characterized with respect to their capacity to stimulate high levels of IFN-γ from human plasmacytoid dendritic cells (pDCs).
75. Smith CA, Woodruff LS, Rooney C, Kitchingman GR. Extensive cross-reactivity of adenovirus-specific cytotoxic T cells. Hum. Gene Ther. 9(10), 1419-1427 (1998). (Pubitemid 28379081)
76. + T cell clones recognizing endogenous antigen inhibit viral replication in vitro through cognate interaction. J. Immunol. 177(12), 8851-8859 (2006).
77. Haveman LM, Bierings M, Legger E et al. Novel pan-DR-binding T cell epitopes of adenovirus induce pro-inflammatory cytokines and chemokines in healthy donors. Int. Immunol. 18(11), 1521-1529 (2006). (Pubitemid 44605573)
78. Sparer TE, Wynn SG, Clark DJ et al. Generation of cytotoxic T lymphocytes against immunorecessive epitopes after multiple immunizations with adenovirus vectors is dependent on haplotype. J. Virol. 71(3), 2277-2284 (1997). (Pubitemid 27078609)
79. Jooss K, Ertl HC, Wilson JM. Cytotoxic T-lymphocyte target proteins and their major histocompatibility complex class I restriction in response to adenovirus vectors delivered to mouse liver. J. Virol. 72(4), 2945-2954 (1998). (Pubitemid 28175532)
80. Leen AM, Sili U, Vanin EF et al. Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. Blood 104(8), 2432-2440 (2004). (Pubitemid 39331844)
81. + T-cell epitope. Hum. Gene Ther. 13(10), 1167-1178 (2002).
82. + cytotoxic T cell responses to adenovirus capsid proteins. Virology 350(2), 312-322 (2006).
83. + T cells. J. Gen. Virol. 90(Pt 1), 84-94 (2009).
84. + T-cell responses are not inhibited by E3-19K in the presence of γ interferon. J. Virol. 70(9), 6314-6322 (1996).
85. Burgert HG, Kvist S. An adenovirus type 2 glycoprotein blocks cell surface expression of human histocompatibility class I antigens. Cell 41(3), 987-997 (1985). (Pubitemid 15243402)
86. Bennett EM, Bennink JR, Yewdell JW, Brodsky FM. Cutting edge: adenovirus E19 has two mechanisms for affecting class I MHC expression. J. Immunol. 162(9), 5049-5052 (1999). (Pubitemid 29307102)
87. Perreau M, Pantaleo G, Kremer EJ. Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J. Exp. Med. 205(12), 2717-2725 (2008).
88. Uberla K. HIV vaccine development in the aftermath of the STEP study: re-focus on occult HIV infection? PLoS Pathog. 4(8), e1000114 (2008).
89. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat. Med. 14(6), 617-621 (2008).
90. Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J. Exp. Med. 205(1), 7-12 (2008).
91. Gahery-Segard H, Farace F, Godfrin D et al. Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J. Virol. 72(3), 2388-2397 (1998). (Pubitemid 28100799)
92. Molinier-Frenkel V, Lengagne R, Gaden F et al. Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J. Virol. 76(1), 127-135 (2002). (Pubitemid 33138998)
93. Wohlfart CE, Svensson UK, Everitt E. Interaction between HeLa cells and adenovirus type 2 virions neutralized by different antisera. J. Virol. 56(3), 896-903 (1985). (Pubitemid 16198734)
94. Toogood CI, Crompton J, Hay RT. Antipeptide antisera define neutralizing epitopes on the adenovirus hexon. J. Gen. Virol. 73(Pt 6), 1429-1435 (1992).
95. Varga MJ, Bergman T, Everitt E. Antibodies with specificities against a dispase-produced 15-kilodalton hexon fragment neutralize adenovirus type 2 infectivity. J. Virol. 64(9), 4217-4225 (1990). (Pubitemid 20279829)
96. Varghese R, Mikyas Y, Stewart PL, Ralston R. Postentry neutralization of adenovirus type 5 by an antihexon antibody. J. Virol. 78(22), 12320-12332 (2004). (Pubitemid 39458751)
97. Sumida SM, Truitt DM, Lemckert AA et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J. Immunol. 174(11), 7179-7185 (2005). (Pubitemid 40705685)
98. Bangari DS, Mittal SK. Current strategies and future directions for eluding adenoviral vector immunity. Curr. Gene Ther. 6(2), 215-226 (2006).
99. Mane VP, Toietta G, McCormack WM et al. Modulation of TNFα, a determinant of acute toxicity associated with systemic delivery of first-generation and helper-dependent adenoviral vectors. Gene Ther. 13(17), 1272-1280 (2006). (Pubitemid 44264081)
100. Price AR, Limberis MP, Wilson JM, Diamond SL. Pulmonary delivery of adenovirus vector formulated with dexamethasone-spermine facilitates homologous vector re-administration. Gene Ther. 14(22), 1594-1604 (2007). (Pubitemid 350056231)
101. Seregin SS, Appledorn DM, McBride AJ et al. Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy. Mol. Ther. 17(4), 685-696 (2009).
102. Ishimoto S, Kawamoto K, Stover T et al. A glucocorticoid reduces adverse effects of adenovirus vectors in the cochlea. Audiol. Neurootol. 8(2), 70-79 (2003). (Pubitemid 36359383)
103. Ramshaw IA, Ramsay AJ. The prime-boost strategy: exciting prospects for improved vaccination. Immunol. Today 21(4), 163-165 (2000). (Pubitemid 30184783)
104. Mastrangeli A, Harvey BG, Yao J et al. 'Sero-switch' adenovirus-mediated in vivo gene transfer: circumvention of antiadenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum. Gene Ther. 7(1), 79-87 (1996). (Pubitemid 126664642)
105. Moffatt S, Hays J, HogenEsch H, Mittal SK. Circumvention of vector-specific neutralizing antibody response by alternating use of human and non-human adenoviruses: implications in gene therapy. Virology 272(1), 159-167 (2000). (Pubitemid 30429439)
106. Farina SF, Gao GP, Xiang ZQ et al. Replication-defective vector based on a chimpanzee adenovirus. J. Virol. 75(23), 11603-11613 (2001). (Pubitemid 33063252)
107. Lemckert AA, Grimbergen J, Smits S et al. Generation of a novel replication-incompetent adenoviral vector derived from human adenovirus type 49: manufacture on PER.C6 cells, tropism and immunogenicity. J. Gen. Virol. 87(Pt 10), 2891-2899 (2006). (Pubitemid 44463897)
108. Shayakhmetov DM, Lieber A. Dependence of adenovirus infectivity on length of the fiber shaft domain. J. Virol. 74(22), 10274-10286 (2000).
109. Kidd AH, Chroboczek J, Cusack S, Ruigrok RW. Adenovirus type 40 virions contain two distinct fibers. Virology 192(1), 73-84 (1993). (Pubitemid 23213228)
110. Yeh HY, Pieniazek N, Pieniazek D, Gelderblom H, Luftig RB. Human adenovirus type 41 contains two fibers. Virus Res. 33(2), 179-198 (1994). (Pubitemid 24300671)
111. Nakamura T, Sato K, Hamada H. Reduction of natural adenovirus tropism to the liver by both ablation of fiber-Coxsackievirus and adenovirus receptor interaction and use of replaceable short fiber. J. Virol. 77(4), 2512-2521 (2003). (Pubitemid 36222775)
112. Shayakhmetov DM, Li ZY, Ni S, Lieber A. Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J. Virol. 78(10), 5368-5381 (2004). (Pubitemid 38581487)
113. Schoggins JW, Nociari M, Philpott N, Falck-Pedersen E. Influence of fiber detargeting on adenovirus-mediated innate and adaptive immune activation. J. Virol. 79(18), 11627-11637 (2005). (Pubitemid 41279281)
114. Schoggins JW, Falck-Pedersen E. Fiber and penton base capsid modifications yield diminished adenovirus type 5 transduction and proinflammatory gene expression with retention of antigen-specific humoral immunity. J. Virol. 80(21), 10634-10644 (2006). (Pubitemid 44628909)
115. Roy S, Gao G, Lu Y et al. Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors. Hum. Gene Ther. 15(5), 519-530 (2004). (Pubitemid 38639622)
116. Kobinger GP, Feldmann H, Zhi Y et al. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 346(2), 394-401 (2006). •• Demonstrates that a single intramuscular injection of AdC7 encoding an Ebola glycoprotein antigen can provide complete, but dose-dependent, protection from lethal Ebola challenge. (Pubitemid 43357883)
117. Zhi Y, Figueredo J, Kobinger GP et al. Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus. Hum. Gene Ther. 17(5), 500-506 (2006). (Pubitemid 43794489)
118. Fitzgerald JC, Gao GP, Reyes-Sandoval A et al. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J. Immunol. 170(3), 1416-1422 (2003). (Pubitemid 36139509)
119. Reyes-Sandoval A, Sridhar S, Berthoud T et al. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur. J. Immunol. 38(3), 732-741 (2008).
120. Sridhar S, Reyes-Sandoval A, Draper SJ et al. Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A. J. Virol. 82(8), 3822-3833 (2008).
121. Xiang Z, Li Y, Cun A et al. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg. Infect. Dis. 12(10), 1596-1599 (2006). (Pubitemid 44570909)
122. Singh N, Pandey A, Jayashankar L, Mittal SK. Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus. Mol. Ther. 16(5), 965-971 (2008). • Investigates homologous and heterologous prime-boost regimens with bovine Ad3 and human Ad5 vectors encoding the H5N1 influenza antigen. In mice with Ad pre-existing immunity (PEI), the Ad3-Ad5 regimen (injected intramuscularly) provided complete protection from lethal influenza challenge, while an Ad5-Ad5 regimen did not.
123. Perreau M, Mennechet F, Serratrice N et al. Contrasting effects of human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of human dendritic cells: implications for clinical efficacy. J. Virol. 81(7), 3272-3284 (2007). (Pubitemid 46456636)
124. Sharma A, Bangari DS, Tandon M et al. Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model. Virology 386(1), 44-54 (2009).
125. Logunov DY, Zubkova OV, Karyagina-Zhulina AS et al. Identification of HI-like loop in CELO adenovirus fiber for incorporation of receptor binding motifs. J. Virol. 81(18), 9641-9652 (2007). (Pubitemid 350067670)
126. Perreau M, Kremer EJ. The conundrum between immunological memory to adenovirus and their use as vectors in clinical gene therapy. Mol. Biotechnol. 34(2), 247-256 (2006). (Pubitemid 46030398)
127. Liu J, Ewald BA, Lynch DM et al. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J. Virol. 82(10), 4844-4852 (2008).
128. Wille-Reece U, Flynn BJ, Lore K et al. Toll-like receptor agonists inf luence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J. Exp. Med. 203(5), 1249-1258 (2006). (Pubitemid 43736594)
129. + T cell responses in nonhuman primates. Proc. Natl Acad. Sci. USA 102(42), 15190-15194 (2005).
130. Mattapallil JJ, Douek DC, Buckler-White A et al. Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J. Exp. Med. 203(6), 1533-1541 (2006). (Pubitemid 43877613)
131. + central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312(5779), 1530-1533 (2006).
132. Liu J, O'Brien KL, Lynch DM et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457(7225), 87-91 (2009).
133. Schirmbeck R, Reimann J, Kochanek S, Kreppel F. The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens. Mol. Ther. 16(9), 1609-1616 (2008). • Provides evidence that, even in naive or B-cell-deficient mice, the Ad-specific T cells generated following vaccination with an antigen-encoding Ad vector can limit the diversity of T cells generated against the antigen.
134. Wu H, Han T, Belousova N et al. Identification of sites in adenovirus hexon for foreign peptide incorporation. J. Virol. 79(6), 3382-3390 (2005). (Pubitemid 40327926)
135. Youil R, Toner TJ, Su Q et al. Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum. Gene Ther. 13(2), 311-320 (2002). (Pubitemid 34164114)
136. Vigne E, Mahfouz I, Dedieu JF et al. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J. Virol. 73(6), 5156-5161 (1999). (Pubitemid 29246779)
137. Roberts DM, Nanda A, Havenga MJ et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441(7090), 239-243 (2006).
138. Kalyuzhniy O, Di Paolo NC, Silvestry M et al. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc. Natl Acad. Sci. USA 105(14), 5483-5488 (2008). • Identifies hexon as the major Ad-binding site for coagulation factor X, and demonstrates hexon mutation can prevent binding and factor X-mediated liver transduction following systemic Ad vector administration in mice. This study further identifies an unsuspected role for Ad hexon in intracellular trafficking of Ad vectors in some cell types, suggesting a need for careful evaluation of hexon-modified Ads.
139. Waddington SN, McVey JH, Bhella D et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132(3), 397-409 (2008). • Identifies hexon as the major Ad-binding site for coagulation factor X, and demonstrates this binding can be blocked by hypervariable region pseudotyping or with factor X-binding protein toxin, preventing liver transduction following systemic Ad vector administration in mice.
140. Crompton J, Toogood CI, Wallis N, Hay RT. Expression of a foreign epitope on the surface of the adenovirus hexon. J. Gen. Virol. 75(Pt 1), 133-139 (1994). (Pubitemid 24033989)
141. Einfeld DA, Brough DE, Roelvink PW, Kovesdi I, Wickham TJ. Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base. J. Virol. 73(11), 9130-9136 (1999). (Pubitemid 29487066)
142. Meulenbroek RA, Sargent KL, Lunde J, Jasmin BJ, Parks RJ. Use of adenovirus protein IX (pIX) to display large polypeptides on the virion: generation of fluorescent virus through the incorporation of pIX-GFP. Mol. Ther. 9(4), 617-624 (2004). (Pubitemid 38578812)
143. Dmitriev IP, Kashentseva EA, Curiel DT. Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J. Virol. 76(14), 6893-6899 (2002). (Pubitemid 41246204)
144. Krause A, Joh JH, Hackett NR et al. Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity. J. Virol. 80(11), 5523-5530 (2006). (Pubitemid 43752798)
145. Vigant F, Descamps D, Jullienne B et al. Substitution of hexon hypervariable region 5 of adenovirus serotype 5 abrogates blood factor binding and limits gene transfer to liver. Mol. Ther. 16(8), 1474-1480 (2008).
146. Worgall S, Krause A, Rivara M et al. Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. J. Clin. Invest. 115(5), 1281-1289 (2005). (Pubitemid 40629047)
147. Matthews QL, Yang P, Wu Q et al. Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach. Virol. J. 5, 98 (2008).
148. Brown BD, Shi CX, Rawle FE et al. Factors influencing therapeutic efficacy and the host immune response to helper-dependent adenoviral gene therapy in hemophilia A mice. J. Thromb. Haemost. 2(1), 111-118 (2004). (Pubitemid 40185627)
149. Kim IH, Jozkowicz A, Piedra PA, Oka K, Chan L. Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc. Natl Acad. Sci. USA 98(23), 13282-13287 (2001). (Pubitemid 33051354)
150. Morral N, O'Neal W, Rice K et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc. Natl Acad. Sci. USA 96(22), 12816-12821 (1999). (Pubitemid 29513585)
151. Kafri T, Morgan D, Krahl T et al. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc. Natl Acad. Sci. USA 95(19), 11377-11382 (1998). (Pubitemid 28450136)
152. Roth MD, Cheng Q, Harui A et al. Helper-dependent adenoviral vectors efficiently express transgenes in human dendritic cells but still stimulate antiviral immune responses. J. Immunol. 169(8), 4651-4656 (2002). (Pubitemid 35178246)
153. Brunetti-Pierri N, Palmer DJ, Beaudet AL et al. Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum. Gene Ther. 15(1), 35-46 (2004). (Pubitemid 38147187)
154. Muruve DA, Cotter MJ, Zaiss AK et al. Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J. Virol. 78(11), 5966-5972 (2004). (Pubitemid 38661684)
155. Wagner E. Converging paths of viral and non-viral vector engineering. Mol. Ther. 16(1), 1-2 (2008).
156. Kreppel F, Kochanek S. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol. Ther. 16(1), 16-29 (2008).
157. O'Riordan CR, Song A. PEGylated adenovirus for targeted gene therapy. Methods Mol. Biol. 434, 133-160 (2008).
158. Eto Y, Yoshioka Y, Mukai Y, Okada N, Nakagawa S. Development of PEGylated adenovirus vector with targeting ligand. Int. J. Pharm. 354(1-2), 3-8 (2008).
159. Romanczuk H, Galer CE, Zabner J et al. Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice. Hum. Gene Ther. 10(16), 2615-2626 (1999).
160. Croyle MA, Chirmule N, Zhang Y, Wilson JM. 'Stealth' adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J. Virol. 75(10), 4792-4801 (2001). (Pubitemid 32381522)
161. Croyle MA, Yu QC, Wilson JM. Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. Hum. Gene Ther. 11(12), 1713-1722 (2000).
162. Eto Y, Gao JQ, Sekiguchi F et al. Neutralizing antibody evasion ability of adenovirus vector induced by the bioconjugation of methoxypolyethylene glycol succinimidyl propionate (MPEGSPA). Biol. Pharm. Bull. 27(6), 936-938 (2004). (Pubitemid 41701823)
163. Eto Y, Gao JQ, Sekiguchi F et al. PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability. J. Gene Med. 7(5), 604-612 (2005). (Pubitemid 40744526)
164. Mok H, Palmer DJ, Ng P, Barry MA. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol. Ther. 11(1), 66-79 (2005). (Pubitemid 40012000)
165. Croyle MA, Le HT, Linse KD et al. PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. Gene Ther. 12(7), 579-587 (2005). (Pubitemid 40468105)
166. De Geest B, Snoeys J, Van Linthout S, Lievens J, Collen D. Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone. Hum. Gene Ther. 16(12), 1439-1451 (2005). (Pubitemid 41829019)
167. Alemany R, Suzuki K, Curiel DT. Blood clearance rates of adenovirus type 5 in mice. J. Gen. Virol. 81(Pt 11), 2605-2609 (2000).
168. Ogawara K, Rots MG, Kok RJ et al. A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum. Gene Ther. 15(5), 433-443 (2004). (Pubitemid 38639615)
169. Lanciotti J, Song A, Doukas J et al. Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. Mol. Ther. 8(1), 99-107 (2003). (Pubitemid 36939301)
170. Ogawara K, Kuldo JM, Oosterhuis K et al. Functional inhibition of NF-κB signal transduction in αvβ3 integrin expressing endothelial cells by using RGD-PEG-modified adenovirus with a mutant IκB gene. Arthritis Res. Ther. 8(1), R32 (2006).
171. Bonsted A, Engesaeter BO, Hogset A et al. Photochemically enhanced transduction of polymer-complexed adenovirus targeted to the epidermal growth factor receptor. J. Gene Med. 8(3), 286-297 (2006).
172. Croyle MA, Chirmule N, Zhang Y, Wilson JM. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum. Gene Ther. 13(15), 1887-1900 (2002). (Pubitemid 35292683)
173. Wortmann A, Vohringer S, Engler T et al. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol. Ther. 16(1), 154-162 (2008).
174. O'Riordan CR, Lachapelle A, Delgado C et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum. Gene Ther. 10(8), 1349-1358 (1999). (Pubitemid 29267589)
175. Hofherr SE, Shashkova EV, Weaver EA, Khare R, Barry MA. Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol. Ther. 16(7), 1276-1282 (2008).
176. Weaver EA, Barry MA. Effects of shielding adenoviral vectors with polyethylene glycol (PEG) on vector-specific and vaccine-mediated immune responses. Hum. Gene Ther. (2008) (Epub ahead of print). •• Systematic investigation of Ad-specific and transgene product-specific immune responses following vaccination with PEGylated Ad vectors in mice. This report evaluates the impact that PEG modifications of various sizes, route of vector administration and identity of the transgene product have on the generation of Ad-neutralizing antibodies and/or T-cell response levels to transgene products.
177. Fisher KD, Stallwood Y, Green NK et al. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. 8(5), 341-348 (2001). (Pubitemid 32241933)
178. Rihova B, Srogl J, Jelinkova M et al. HPMA-based biodegradable hydrogels containing different forms of doxorubicin. Antitumor effects and biocompatibility. Ann. NY Acad. Sci. 831, 57-71 (1997). (Pubitemid 28045264)
179. Carlisle RC, Di Y, Cerny AM et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood 113(9), 1909-1918 (2009).
180. Zhou QH, Miller DL, Carlisle RC, Seymour LW, Oupicky D. Ultrasound-enhanced transfection activity of HPMA-stabilized DNA polyplexes with prolonged plasma circulation. J. Control. Release 106(3), 416-427 (2005). (Pubitemid 41187450)
181. Green NK, Morrison J, Hale S et al. Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer. J. Gene Med. 10(3), 280-289 (2008).
182. Green NK, Herbert CW, Hale SJ et al. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther. 11(16), 1256-1263 (2004). (Pubitemid 39173432)
183. Goldman CK, Rogers BE, Douglas JT et al. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res. 57(8), 1447-1451 (1997). (Pubitemid 27175559)
184. Douglas JT, Rogers BE, Rosenfeld ME et al. Targeted gene delivery by tropism-modified adenoviral vectors. Nat. Biotechnol. 14(11), 1574-1578 (1996). (Pubitemid 26365552)
185. Wickham TJ, Segal DM, Roelvink PW et al. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J. Virol. 70(10), 6831-6838 (1996). (Pubitemid 26307394)
186. Tillman BW, de Gruijl TD, Luykx-de Bakker SA et al. Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J. Immunol. 162(11), 6378-6383 (1999). (Pubitemid 29309357)
187. Pereboev AV, Asiedu CK, Kawakami Y et al. Coxsackievirus-adenovirus receptor genetically fused to anti-human CD40 scFv enhances adenoviral transduction of dendritic cells. Gene Ther. 9(17), 1189-1193 (2002). (Pubitemid 34993942)
188. Pereboev AV, Nagle JM, Shakhmatov MA et al. Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule. Mol. Ther. 9(5), 712-720 (2004). (Pubitemid 38660424)
189. + cells. Gene Ther. 15(4), 298-308 (2008). • Expansive investigation comparing the effects of administration route on relative levels of organ-specific transgene expression in mice injected with untargeted or CD40-targeted Ad5 vectors.
190. Santosuosso M, Zhang X, McCormick S et al. Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen. J. Immunol. 174(12), 7986-7994 (2005). (Pubitemid 40806309)
191. Croyle MA, Patel A, Tran KN et al. Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS ONE 3(10), e3548 (2008). •• Demonstrates that intranasal, but not intramuscular or oral, administration of an Ad5 vector encoding an Ebola antigen provides complete protection against lethal Ebola challenge in mice with Ad5 PEI.
192. Patel A, Zhang Y, Croyle M et al. Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice. J. Infect. Dis. 196(Suppl. 2), S413-S420 (2007).
193. Kiyono H, Fukuyama S. NALT- versus Peyer's-patch-mediated mucosal immunity. Nat. Rev. Immunol. 4(9), 699-710 (2004). (Pubitemid 39223076)
194. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6(2), 148-158 (2006). (Pubitemid 43361590)
195. Xiang ZQ, Gao GP, Reyes-Sandoval A et al. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J. Virol. 77(20), 10780-10789 (2003). (Pubitemid 37204271)
196. Hashimoto M, Boyer JL, Hackett NR, Wilson JM, Crystal RG. Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity. Infect. Immun. 73(10), 6885-6891 (2005). (Pubitemid 41368857)
197. Appaiahgari MB, Saini M, Rauthan M, Jyoti, Vrati S. Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis. Microbes Infect. 8(1), 92-104 (2006). (Pubitemid 43139296)
198. Zhou D, Cun A, Li Y, Xiang Z, Ertl HC. A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus. Mol. Ther. 14(5), 662-672 (2006). (Pubitemid 44480754)
199. Van Kampen KR, Shi Z, Gao P et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23(8), 1029-1036 (2005). (Pubitemid 40037652)
200. Lemiale F, Kong WP, Akyurek LM et al. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J. Virol. 77(18), 10078-10087 (2003). (Pubitemid 37122089)
201. Doi K, Nibu K, Ishida H, Okado H, Terashima T. Adenovirus-mediated gene transfer in olfactory epithelium and olfactory bulb: a long-term study. Ann. Otol. Rhinol. Laryngol. 114(8), 629-633 (2005). (Pubitemid 41170054)
202. Damjanovic D, Zhang X, Mu J, Fe Medina M, Xing Z. Organ distribution of transgene expression following intranasal mucosal delivery of recombinant replication-defective adenovirus gene transfer vector. Genet. Vaccines Ther. 6, 5 (2008).
203. Zabaleta A, Llopiz D, Arribillaga L et al. Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein. Mol. Ther. 16(1), 210-217 (2008).
204. Proudfoot O, Apostolopoulos V, Pietersz GA. Receptor-mediated delivery of antigens to dendritic cells: anticancer applications. Mol. Pharm. 4(1), 58-72 (2007). (Pubitemid 46302129)
205. Casimiro DR, Wang F, Schleif WA et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J. Virol. 79(24), 15547-15555 (2005). (Pubitemid 43032336)
206. Isman O, Roberts ML, Morgan JE et al. Adenovirus-based targeting in myoblasts is hampered by nonhomologous vector integration. Hum. Gene Ther. 19(10), 1000-1008 (2008).
207. Ohbayashi F, Balamotis MA, Kishimoto A et al. Correction of chromosomal mutation and random integration in embryonic stem cells with helper-dependent adenoviral vectors. Proc. Natl Acad. Sci. USA 102(38), 13628-13633 (2005). (Pubitemid 41420899)
208. Fehse B, Roeder I. Insertional mutagenesis and clonal dominance: biological and statistical considerations. Gene Ther. 15(2), 143-153 (2008).
209. + T cells are maintained and central memory cells are created, which may offer even greater vaccine efficacy.
210. Seiradake E, Henaff D, Wodrich H et al. The cell adhesion molecule 'CAR' and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution. PLoS Pathog. 5(1), e1000277 (2009).
211. US FDA www.fda.gov